Research graph
References from Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src. Local targets link to admitted publications; unresolved targets remain external evidence.
Management and treatment of non-small cell lung cancer with MET alteration and mechanisms of resistance
10.1007/s11864-022-01019-2 · 2022 · External reference
Targeting c-Met in the treatment of urologic neoplasms: current status and challenges
10.3389/fonc.2023.1071030 · 2023 · External reference
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
10.1186/s13045-019-0759-9 · 2019 · External reference
10.1007/s10120-015-0585-x
10.1007/s10120-015-0585-x · External reference
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
10.1002/hep.29496 · 2018 · External reference
Roles of MET in human cancer
10.1016/j.cca.2021.12.017 · 2022 · External reference
10.1038/s41571-020-0377-z
10.1038/s41571-020-0377-z · External reference
MET alterations in advanced non-small cell lung cancer
10.1016/j.lungcan.2023.02.018 · 2023 · External reference
10.1038/s41416-019-0573-8
10.1038/s41416-019-0573-8 · External reference
The role of cMET in gastric cancer-a review of the literature
10.3390/cancers15071976 · 2023 · External reference
Targeting MET: discovery of small molecule inhibitors as non-small cell lung cancer therapy
10.1021/acs.jmedchem.3c00028 · 2023 · External reference
c-met signaling as a therapeutic target in head and neck cancer
10.1097/ppo.0000000000000619 · 2022 · External reference
10.1007/s40265-021-01477-2
10.1007/s40265-021-01477-2 · External reference
10.1016/j.jtho.2016.05.005
10.1016/j.jtho.2016.05.005 · External reference
10.1158/1535-7163.mct-17-0368
10.1158/1535-7163.mct-17-0368 · External reference
Safety and tolerability of c-MET inhibitors in cancer
10.1007/s40264-018-0780-x · 2019 · External reference
Tepotinib: first approval
10.1007/s40265-020-01317-9 · 2020 · External reference
Savolitinib: first approval
10.1007/s40265-021-01584-0 · 2021 · External reference
Capmatinib: first approval
10.1007/s40265-020-01347-3 · 2020 · External reference
Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses
10.1158/1538-7445.am2019-1325 · 2019 · External reference
Abstract 1444: TPX-0022, a potent MET/SRC/CSF1R inhibitor that modulates the tumor immune microenvironment in preclinical models
2021 · External reference
Recent advances in macrocyclic drugs and microwave-assisted and/or solid-supported synthesis of macrocycles
2022 · External reference
Unresolved reference
External reference
Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase
10.1021/acs.jmedchem.2c00962 · 2023 · External reference
10.1016/j.jtho.2019.06.023
10.1016/j.jtho.2019.06.023 · External reference
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
10.1039/c8cc07546h · 2018 · External reference
Upgrade of macromolecular crystallography beamline BL17U1at SSRF
2018 · External reference
10.1007/s41365-019-0683-2
10.1007/s41365-019-0683-2 · External reference
Acta crystallographica section D biological crystallography
2013 · External reference
10.1107/s2059798319011471
10.1107/s2059798319011471 · External reference
10.1021/acsmedchemlett.9b00276
10.1021/acsmedchemlett.9b00276 · External reference
10.1107/s0907444910007493
10.1107/s0907444910007493 · External reference
Unresolved reference
External reference
10.1002/jcc.21256
10.1002/jcc.21256 · External reference
10.1038/srep42717
10.1038/srep42717 · External reference
Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors
10.1021/acs.jmedchem.9b01169 · 2019 · External reference
10.1021/acs.jmedchem.2c00981
10.1021/acs.jmedchem.2c00981 · External reference
10.1126/science.1131943
10.1126/science.1131943 · External reference
10.1016/j.chembiol.2016.07.017
10.1016/j.chembiol.2016.07.017 · External reference
Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations
10.1158/1535-7163.mct-21-0632 · 2021 · External reference
10.1021/acs.jmedchem.1c00217
10.1021/acs.jmedchem.1c00217 · External reference
Lorlatinib: first global approval
10.1007/s40265-018-1041-0 · 2019 · External reference
10.1021/jm2007613
10.1021/jm2007613 · External reference
10.1158/1078-0432.ccr-19-3608
10.1158/1078-0432.ccr-19-3608 · External reference
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
10.1186/s13045-022-01299-z · 2022 · External reference
